The National Institute of Allergy and Infectious Diseases (NIAID) Radiation and Nuclear Countermeasures Program has awarded $23.6 million in new contracts to advance development of drugs for treating radiation-induced injuries and improving survival during a radiological or nuclear public health emergency. These investigational drugs are designed to fill specific gaps in the set of FDA-approved treatments for radiation-induced injuries by targeting early gut injuries, late lung injuries, and bone marrow injuries that receive delayed therapy. The awards also address an unmet need by funding the development of a portable device for assessing radiation exposure to help healthcare providers triage and manage patients during a radiation mass casualty incident.
The recipient organizations are as follows:
Advanced Development of BBT-059 as a Radiation Medical Countermeasure for Dosing up to 48 Hours Post-Exposure
- Contractor Name: Bolder Biotechnology Inc
- Contractor Address: Louisville, CO 80027 USA
- Base and All Options Value: $3,079,368.00
Development of Anticeramide Treatment as a Novel Medical Countermeasure for Acute Effects of Radiation Exposure
- Contractor Name: Ceramedix Holding, LLC
- Contractor Address: New York, NY 10022 USA
- Base and All Options Value: $4,321,240.00
Development of IPW-5371 Fumarate as a Radiation MCM for Treatment of Delayed Radiation Lung Injury Under the FDA Animal Rule
- Contractor Name: Innovation Pathways LLC
- Contractor Address: Palo Alto, CA 94301 USA
- Base and All Options Value: $4,499,688.00
Development of Anticeramide Treatment as a Novel Medical Countermeasure for Acute Effects of Radiation Exposure
- Contractor Name: The Medical College of Wisconsin, Inc.
- Contractor Address: Milwaukee, WI 53226 USA
- Base and All Options Value: $2,997,981.00
Development of PLX-R18 Cell Therapy as a Countermeasure for Hematopoietic Acute Radiation Syndrome
- Contractor Name: Pluri Biotech Ltd
- Contractor Address: Haifa ISR
- Base and All Options Value: $4,175,466.00
A microRNA Biodosimeter
- Contractor Name: Chromologic LLC
- Contractor Address: Monrovia, CA 91016 USA
- Base and All Options Value: $4,498,029.0
The funding was awarded under Broad Agency Announcement (BAA) HHS-NIH-NIAID-BAA-75N93021R00019, which solicited investigator-initiated, advanced development research directed toward Investigational New Drug application (IND) or Investigational Use Only (IUO)-enabling efforts for the development of medical countermeasures and biodosimetry approaches.
Source: Sam.gov